Gene · 1540
Papers3,467
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,467
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel missense pathogenic variant in the CYLD gene in a Chinese family with multiple familial trichoepithelioma. | Int J Dermatol | 2024 | 38780099 | PubTator, text mining | PubMed |
| R-loop and diseases: the cell cycle matters. | Mol Cancer | 2024 | 38678239 | PubTator, text mining | PubMed |
| A Misdiagnosed Familiar Brooke-Spiegler Syndrome: Case Report and Review of the Literature. | J Clin Med | 2024 | 38673513 | PubTator, text mining | PubMed |
| The TRIF-RIPK1-Caspase-8 signalling in the regulation of TLR4-driven gene expression. | Immunology | 2024 | 38618995 | PubTator, text mining | PubMed |
| Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review. | Medicine (Baltimore) | 2024 | 38579060 | PubTator, text mining | PubMed |
| The emerging roles of non-canonical ubiquitination in proteostasis and beyond. | J Cell Biol | 2024 | 38517379 | PubTator, text mining | PubMed |
| RIPK3 cleavage is dispensable for necroptosis inhibition but restricts NLRP3 inflammasome activation. | Cell Death Differ | 2024 | 38514849 | PubTator, text mining | PubMed |
| Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment. | Cancer Rep (Hoboken) | 2024 | 38477073 | PubTator, text mining | PubMed |
| A novel splicing CYLD variant associated with trichoepithelioma papulosum multiplex demonstrating intrafamilial severity variability. | J Dermatol | 2024 | 38444102 | PubTator, text mining | PubMed |
| Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report. | Hum Vaccin Immunother | 2024 | 38348622 | PubTator, text mining | PubMed |
| TNF and IFNγ-induced cell death requires IRF1 and ELAVL1 to promote CASP8 expression. | J Cell Biol | 2024 | 38319288 | PubTator, text mining | PubMed |
| Inhibition of pancreatic lipase by coffee leaves-derived polyphenols: A mechanistic study. | Food Chem | 2024 | 38310782 | PubTator, text mining | PubMed |
| Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairment. | Front Cell Dev Biol | 2024 | 38298218 | PubTator, text mining | PubMed |
| CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma. | Cell Death Dis | 2024 | 38287022 | PubTator, text mining | PubMed |
| Mapping the landscape of HPV integration and characterising virus and host genome interactions in HPV-positive oropharyngeal squamous cell carcinoma. | Clin Transl Med | 2024 | 38279874 | PubTator, text mining | PubMed |
| SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation. | Clin Transl Med | 2024 | 38279869 | PubTator, text mining | PubMed |
| LUBAC promotes angiogenesis and lung tumorigenesis by ubiquitinating and antagonizing autophagic degradation of HIF1α. | Oncogenesis | 2024 | 38272870 | PubTator, text mining | PubMed |
| UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1 [Retraction]. | Onco Targets Ther | 2024 | 38264454 | PubTator, text mining | PubMed |
| Aberrant DNA Methylation of NPTX2 as an Indicator of Malignant Behavior in Thymic Epithelial Tumors. | Cancers (Basel) | 2024 | 38254821 | PubTator, text mining | PubMed |
| The miR-19a/Cylindromatosis Axis Regulates Pituitary Adenoma Bone Invasion by Promoting Osteoclast Differentiation. | Cancers (Basel) | 2024 | 38254792 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1540/papers?page=9